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Role of HLA-DR in the Pathogenesis of Abdominal Aortic Aneurysm
G. MonÄux1, F. J. Serrano1, P. Vigil2 and E. G. De la Concha2
Departments of 1Angiology and Vascular Surgery and 2Immunology, Hospital ClõÂnico San Carlos, Madrid, Spain
Objective: to establish a possible role for autoimmunity in the aetiology of abdominal aortic aneurysm (AAA) by
examining human leukocyte antigen class II (HLA-II) immune response genes.
Materials and Methods: HLA-II typing was performed in a series of 72 AAA patients and a control group of 380 healthy
subjects.
Results: a higher incidence of the allele subtype HLA-DR B1*0401 was detected in the AAA group with respect to the
control group (12.5 vs 5.2%; p 0.02, OR 2.59). In contrast, the HLA-DR B1*01 allele tended to behave as a protective
factor for AAA (12.5% AAA vs 21.3% controls; p 0.09, OR 0.5).
Conclusions: the association observed here between HLA-DR B1*0401 and HLA-DR B1*01 and unspecific AAA is
similar to that reported in several autoimmune diseases. This similarity suggests an essential role for autoimmune factors in
the formation of the AAA.
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Introduction
The aetiology of abdominal aortic aneurysm (AAA)
remains unclear. The possible role played by auto-
immunity, and its relationship with matrix metallo-
proteinases, remains inconclusive.1±5 In autoimmune
diseases, the major human histocompatibility com-
plex is known to be involved in the presentation of
autoantigens to host immune cells. Tilson et al.6 and
Hiroshe et al.7 reported an association between the
human leukocyte antigen class II (HLA-II) immune
response gene HLA-DR2 and AAA in two studies
performed on small series of Black and Japanese
populations, respectively. Rassmussen et al.8 were also
able to associate HLA-DR2 and HLA-DR4 with AAA.
This study was designed to evaluate possible associa-
tions between alleles of the HLA-II immune response
gene and AAA in a European population group.
Materials and Methods
The 11 main alleles of the HLA-DR B1 locus were
typed in a group of 72 consecutive patients who had
undergone infra-renal AAA repair. Patients with an
inflammatory aneurysm and those showing signs or
family history of an autoimmune disease were
excluded from the study. All the patients were white
and born in Spain with Spanish ancestors. The usual
risk factors were present (Table 1). The control group
comprised 380 white subjects with no known auto-
immune disease or cardiovascular pathology. They
were all Spanish, live in the number seven health
area in Madrid, and a representative sample of our
community. These subjects were recruited from our
centre to establish a DNA bank for use as the control
group in several autoimmune pathology studies.
DNA was extracted from leukocytes previously iso-
lated from 10 ml blood samples preserved in EDTA as
the anticoagulant at 4 C until processing. Once the
DNA was extracted, amplification of the relevant
gene sequence was performed by polymerase chain
reaction (PCR) to provide a sufficient number of
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Table 1. Risk factors of the AAA group (n 72).
COPD: chronic obstructive pulmonary disease.
n (%)
Smoking 62 (86.1)
Hypertension 40 (55.6)
Coronary artery disease 24 (33.3)
COPD 17 (23.6)
Sex/male 70 (97.2)
Age (median sd) 67 14.7
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copies to work with. The reaction mixture was pro-
cessed in a thermocycler under the following condi-
tions: initial hybridisation at 95 C for 4 min, 35 cycles
of 20 s at 95 C, 20 s at 55 C and 30 s at 72 C, and a
final extension stage of 7 min at 72 C. EcoTaq DNA
polymerase was the enzyme used for amplification.
The different HLA-DR B1 alleles were identified
using specific oligonucleotide probes (Dot-Blot)
according to the method described by Verduyn et al.9
The probes are DNA fragments whose base sequence
is complementary to the sequence to be identified.
These probes are labelled with digoxygenin-ddUTP,
such that the different alleles can be detected by devel-
oping photographic plates exposed to the marker.
The DNA typing data were introduced into a
Microsoft Access database. Statistical analysis was per-
formed using the Epi-info programme by the 2-test
(using Yates' or Fischer's correction when needed) to
compare the patient and control groups. The level of
statistical significance was set at p5 0.05. The asso-
ciated risk of AAA was evaluated in terms of the odds
ratio (OR) and 95% confidence interval (95% CI).
Results
No significant differences were detected in the fre-
quencies of the different HLA-DR alleles between the
patient and control groups (Table 2). However, the
HLA-DR B101 allele showed a tendency to behave
as a protective factor against AAA. This allele showed
an incidence of 12.5%, compared to 21.3% recorded in
the healthy control group (p 0.09; OR 0.5, 95% CI
0.23±1.15). In contrast, the HLA-DR B104 allele
showed a predisposing tendency for the disease with
a 30.5% incidence in the AAA group, compared to
21.1% in the healthy controls (p 0.08; OR 1.7, 95%
CI 0.90±2.98). To establish whether these tendencies
were attributable to certain subtypes of these alleles,
we also determined subtype frequencies. No signifi-
cant difference was detected in the incidence of the
HLA-DR B101 subtypes between the two groups
(Table 3). However, the 0401 subtype of the HLA-
DR B104 allele did appear as a risk factor for AAA,
showing an incidence of 12.5% compared to the 5.2%
shown by the control group (p 0.02; OR 2.6, 95% CI
1.03±6.3) (Table 4).
Discussion
The role of inflammatory cells in the aetiology of AAA
is currently being explored by several investigators,
who have attempted to establish a relationship
between the disease and the expression of certain
metalloproteinases that might alter the normal struc-
ture of collagen and elastin in the aortic wall.1±5 In a
histological study, in which several lymphocyte popu-
lations were quantified using monoclonal antibodies,
Koch et al.10 demonstrated altered amounts of these
populations in aortic arteriosclerosis. These authors
suggested the occurrence of an inflammatory process
in the aortic wall as a response to autoimmune insult.
Increased levels of metalloproteinases such as strepto-
melisin (MMP 3), collagenase (MMP 1) and gelatinase
B (MMP 9) in the aortic wall are thought to modify
the normal structure of collagen and elastin in the
adventitial layer of the aorta leading to its dilation.
The rise in levels of these proteolytic enzymes is
induced by cytokines such as the tumour necrosis
factor and interleukin-1, which are found in increased
amounts in the aortic wall.4,11±14 Tilson et al.6 demon-
strated how an Ig-G immunoglobulin purified from
the wall of the AAA was immunoreactive with an
Table 2. Incidence of HLA-DR B1 alleles in patients with AAA
and healthy controls.
AAA (%)
(n 72)
Control (%)
(n 380)
p-value OR 95% CI
DR B101 12.5 21.3 0.09 0.5 0.23±1.15
DR B102 25 26.6 0.7 0.9 0.49±1.70
DR B103 30.5 24.7 0.3 1.9 0.74±240
DR B104 30.5 21.1 0.08 1.7 0.90±2.98
DR B105 26.4 29.2 0.62 0.8 0.47±1.58
DR B107 37.5 28.2 0.1 0.6 0.87±2.67
DR B108 5 7.6 0.7 0.7 0.20±2.21
DR B109 1.4 1.6 0.9 1.5 0.21±8.17
DR B1010 2.8 1.8 0.9 1.5 0.21±8.21
DR B1011 16.7 22.9 0.24 0.6 0.32±1.36
DR B1012 1.4 1.3 1 1.05 0.12±9.18
Table 3. Incidence of HLA-DR B101 subtypes in patients with
AAA and healthy controls.
AAA (%)
(n 72)
Control (%)
(n 380)
p-value OR 95% CI
DR B10101 9.7 12.3 0.7 0.6 0.30±1.85
DR B10102 1.4 6.3 0.2 0.1 0.02±1.58
DR B10103 1.4 1.8 0.9 0.8 0.09±6.19
Table 4. Incidence of HLA-DR B104 subtypes in patients with
AAA and healthy controls.
AAA (%)
(n 72)
Control (%)
(n 380)
p-value OR 95% CI
DR B10401 12.5 5.2 0.02 2.6 1.03±6.3
DR B10402 4.2 2.6 0.47 1.6 0.34±6.55
DR B10403 2.8 1.6 0.47 1.7 0.24±10
DR B10404 5.6 4.9 0.8 1.1 0.31±3.63
DR B10405 2.8 3.7 0.7 0.7 0.11±3.55
DR B10407 1.3 0.2 0.7 5.3 ÿ 8.1±197
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80 Kd protein of the normal aortic wall, and that this
protein was located in the adventitia. This Ig±G iso-
lated from the AAA wall, therefore, acts as an auto-
antibody against a protein normally found in the
aortic adventitia.15 This reaction could thus trigger
the inflammatory process giving rise to the increase
in cytokines and, in turn, to the rise in metalloprotei-
nases, inducing the degradation of the aortic wall.
There are, therefore, many features that suggest
that AAA could be of an autoimmune nature. In this
type of disease, the human major histocompatibility
complex, particularly the HLA-DR antigen, plays a
key role. Thus, the prototype autoimmune disease,
rheumatoid arthritis, has been associated with the
presence of the HLA-DR B10401 allele.16 Some
authors have also demonstrated a relationship
between HLA-DR B102 and AAA. Tilson et al.6
were able to observe such a relationship in a small
group of Black North Americans. Rasmussen et al.17
reported similar results in a North American popula-
tion with inflammatory AAA. In a similar study per-
formed on 46 Japanese patients with AAA and 50
healthy controls, Hirose et al.7 confirmed Rasmussen's
results for the mixed North American population.
Moreover, Rasmussen et al.8 recently published a fur-
ther study in which they were able to note an associ-
ation between HLA-DR B102 and HLA-DR B104
and AAA. These authors also observed that HLA-DR
B101 behaved as a protecting factor for this disease.
These findings are in part similar to those observed
here, in that we found the same associations between
AAA and the DR B104 and DR B101 alleles. Further,
we were able to identify the DR B104 subtype
responsible for the genetic susceptibility which appe-
ared as a risk factor for the development of AAA
(p 0.03; OR 2.6, 95% CI 1.03±6.3). It should be high-
lighted that this is the first study to identify the allele
subtype responsible for this association. Though
similar interactions have been reported in other dis-
eases of an autoimmune character. As mentioned
above, the HLA-DR B10401 subtype has been asso-
ciated with the typically autoimmune disease rheuma-
toid arthritis.16 These two diseases do not have any
apparent relationship. This could be explained by
linkage disequilibrium. HLA-DR B10401 is asso-
ciated with severe forms of rheumatoid arthritis.
This does not mean that this gene is responsible for
the development of the disease, but it marks a suscep-
tibility to suffer it because it is inherited with a gene
which encodes an inflamation factor and which is
placed very close by in tha DNA chain. This is applic-
able to our case and to most of currently classified as
autoimmune diseases. The difference could lie in the
autoantigen which starts the disease. Besides, there is
a similarity between two diseases: In rheumatoid arth-
ritis the sinovia is actively infiltrated by limphocytes,
mainly CD4 cells, surrounding the tissue vessels. This
same phenomenon occurs in AAA, as Koch et al.10
described. Reduced HLA-DR B101 expression has
also been described in giant cell arthritis, an auto-
immune disease involving the inflammation of the
arterial wall.18 In our study performed on a Spanish
population, no relationship between HLA-DR B102
and AAA, such as that observed in American and
Japanese patients, was detected. The fact that AAA
has been linked to different alleles depending on the
study population could reflect genetic variation
among races, such as occurs in other autoimmune
diseases.
In conclusion, the results of this and other studies
suggest that autoimmune phenomena can play an
important role at some stage in the aetiology of the
AAA. These findings could have implications in new
diagnostic applications. The over two-fold increase in
the risk of AAA associated with HLA-DR B10401 is
sufficient to consider it a genetic marker, which could
be used for screening populations at risk of cardio-
vascular disease. From a therapeutic stand-point, this
association suggests the possibility of applying immu-
nomodulatory agents to inhibit the inflammatory
process and thus stall aneurysm enlargement. Not-
withstanding, it is clear that much further work in
this field is needed if we are to fully understand the
role of inflammation and autoimmunity in the genesis
of what is presently refered to as an unspecific
aneurysm of the abdominal aorta.
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